Davita Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while Vanguard Dividend Appreciation Index Fund ETF trades at $238.99 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 11.7× Davita Inc's market cap, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| DVA | VIG | |
|---|---|---|
Market Cap | $11.29B | $132.40B |
Volume | 582,204 | 1,287,188 |
Sector | Health | — |
52-Week High | $240.96 | $246.61 |
52-Week Low | $103.87 | $210.70 |
Typical Hold Time | 114 Days | 134 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
VIG trades at $239.00, up 0.85% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights its role in retirement portfolios and a 7.5% quarterly dividend increase, though year-to-date growth remains modest at 3.3%.
Outlook remains positive given VIG's quality focus and historical 10% annual returns, but risks include slow dividend growth and exclusion of high-yield stocks. The ETF suits investors seeking steady income with growth potential, though competition from SCHD and market volatility pose challenges to outperformance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →